Reference
[1] Seror R, Nocturne G, Mariette X. Current and future therapies for primary Sjögren syndrome[J]. Nature reviews. Rheumatology, 2021,17(8):475-486.
[2] Wang J, Zhou L, Liu B. Update on disease pathogenesis, diagnosis, and management of primary Sjögren’s syndrome[J]. International journal of rheumatic diseases, 2020,23(6):723-727.
[3] Chivasso C, Sarrand J, Perret J, et al. The Involvement of Innate and Adaptive Immunity in the Initiation and Perpetuation of Sjögren’s Syndrome[J]. International Journal of Molecular Sciences, 2021,22(2):658.
[4] Cheng L, Liu L, Su R, et al. The decreased of peripheral blood natural killer cell is associated with serum IL-2 level in the renal tubular acidosis in patients with primary sjogren’s syndrome[J]. BMC Immunology, 2023,24(1):17.
[5] Sato M, Arakaki R, Tawara H, et al. Disturbed natural killer cell homeostasis in the salivary gland enhances autoimmune pathology via IFN-γ in a mouse model of primary Sjögren’s syndrome[J]. Frontiers in Medicine, 2022,9:1036787.
[6] Ming B, Wu T, Cai S, et al. The Increased Ratio of Blood CD56bright NK to CD56dim NK Is a Distinguishing Feature of Primary Sjögren’s Syndrome[J]. Journal of Immunology Research, 2020,2020:1-7.
[7] Mesci A, Ljutic B, Makrigiannis AP, et al. NKR-P1 biology: from prototype to missing self[J]. Immunol Res, 2006,35(1):13-26.
[8] Braud V M, Meghraoui-Kheddar A, Elaldi R, et al. LLT1-CD161 Interaction in Cancer: Promises and Challenges[J]. Frontiers in immunology, 2022,13:847576.
[9] Aldemir H, Prod’Homme V, Dumaurier MJ, et al. Cutting Edge: Lectin-Like Transcript 1 Is a Ligand for the CD161 Receptor[J]. J Immunol, 2005,175(12):7791-7795.
[10] Rosen DB, Cao W, Avery DT, et al. Functional consequences of interactions between human NKR-P1A and its ligand LLT1 expressed on activated dendritic cells and B cells[J]. J Immunol, 2008,180(10):6508-6517.
[11] Zhao L, Nocturne G, Haskett S, et al. Clinical relevance of RORγ positive and negative subsets of CD161+CD4+T cells in primary Sjögren’s syndrome[J]. Rheumatology, 2017,56(2):303-312.
[12] Li L, He J, Zhu L, et al. The Clinical Relevance of IL-17-Producing CD4+CD161+ Cell and Its Subpopulations in Primary Sjogren’s Syndrome[J]. J Immunol Res, 2015,2015:307453.
[13] Negrini S, Emmi G, Greco M, et al. Sjögren’s syndrome: a systemic autoimmune disease[J]. Clinical and Experimental Medicine, 2022,22(1):9-25.
[14] Seror R, Theander E, Brun J G, et al. Validation of EULAR primary Sjogren’s syndrome disease activity (ESSDAI) and patient indexes (ESSPRI)[J]. Ann Rheum Dis, 2015,74(5):859-866.
[15] Seror R, Bootsma H, Saraux A, et al. Defining disease activity states and clinically meaningful improvement in primary Sjögren’s syndrome with EULAR primary Sjögren’s syndrome disease activity (ESSDAI) and patient-reported indexes (ESSPRI)[J]. Ann Rheum Dis., 2016,75(2):382-389.
[16] Zeng W, Zhou X, Yu S, et al. The Future of Targeted Treatment of Primary Sjogren’s Syndrome: A Focus on Extra-Glandular Pathology[J]. Int J Mol Sci, 2022,23(22):14135.
[17] Ritter J, Chen Y, Stefanski A, et al. Current and future treatment in primary Sjögren’s syndrome – A still challenging development[J]. Joint Bone Spine, 2022,89(6):105406.
[18] Padilla C M, Valenzi E, Tabib T, et al. Increased CD8+ tissue resident memory T cells, regulatory T cells and activated natural killer cells in systemic sclerosis lungs[J]. Rheumatology, 2023(6):d273.
[19] Luo Q, Kong Y, Fu B, et al. Increased TIM-3+PD-1+ NK cells are associated with the disease activity and severity of systemic lupus erythematosus[J]. Clinical and Experimental Medicine, 2022,22(1):47-56.
[20] Lu Z, Tian Y, Bai Z, et al. Increased oxidative stress contributes to impaired peripheral CD56dimCD57+ NK cells from patients with systemic lupus erythematosus[J]. Arthritis Research & Therapy, 2022,24(1):48.
[21] Hydes T J, Blunt M D, Naftel J, et al. Constitutive Activation of Natural Killer Cells in Primary Biliary Cholangitis[J]. Frontiers in Immunology, 2019,10:2633.
[22] Almeida I, Silva S V, Fonseca A R, et al. T and NK Cell Phenotypic Abnormalities in Systemic Sclerosis: a Cohort Study and a Comprehensive Literature Review[J]. Clinical Reviews in Allergy & Immunology, 2015,49(3):347-369.
[23] Kurioka A, Cosgrove C, Simoni Y, et al. CD161 Defines a Functionally Distinct Subset of Pro-Inflammatory Natural Killer Cells[J]. Frontiers in Immunology, 2018,9:486.
[24] Lanier L L, Chang C, Phillips J H. Human NKR-P1A. A disulfide-linked homodimer of the C-type lectin superfamily expressed by a subset of NK and T lymphocytes[J]. The Journal of immunology (1950), 1994,153(6):2417-2428.
[25] Wyrożemski Ł, Qiao S W. Immunobiology and conflicting roles of the human CD161 receptor in T cells[J]. Scandinavian Journal of Immunology, 2021,94(3):e13090.
[26] Park Y, Lim J, Kim S Y, et al. Changes of frequency and expression level of CD161 in CD8+ T cells and natural killer T cells in peripheral blood of patients with systemic lupus erythematosus[J]. Microbiology and Immunology, 2020,64(7):532-539.
[27] Lin Y, Lin S. Analysis of the CD161-expressing cell quantities and CD161 expression levels in peripheral blood natural killer and T cells of systemic lupus erythematosus patients[J]. Clinical and Experimental Medicine, 2017,17(1):101-109.
[28] Rai A K, Thakur C P, Kumar P, et al. Decrease in the Frequency of Circulating CD56+CD161+ NK Cells in Human Visceral Leishmaniasis[J]. Immunological investigations, 2018,47(2):125-134.
[29] Lenart M, Górecka M, Bochenek M, et al. SARS-CoV-2 infection impairs NK cell functions via activation of the LLT1-CD161 axis[J]. Frontiers in Immunology, 2023,14:1123155.
[30] Rosen D B, Cao W, Avery D T, et al. Functional Consequences of Interactions between Human NKR-P1A and Its Ligand LLT1 Expressed on Activated Dendritic Cells and B Cells1[J]. The Journal of immunology (1950), 2008,180(10):6508-6517.
[31] Bambard N D, Mathew S O, Mathew P A. LLT1‐mediated Activation of IFN‐γ Production in Human Natural Killer Cells Involves ERK Signalling Pathway[J]. Scandinavian Journal of Immunology, 2010,71(3):210-219.
[32] David Pozo, Mar Valés-Gómez, Nasim Mavaddat, et al. CD161 (Human NKR-P1A) Signaling in NK Cells Involves the Activation of Acid Sphingomyelinase[J]. J Immunol, 2006,176(4):2397-2406.
[33] Du W, Han M, Zhu X, et al. The Multiple Roles of B Cells in the Pathogenesis of Sjögren’s Syndrome[J]. Frontiers in Immunology, 2021,12:684999.
[34] Gyurova I E, Ali A, Waggoner S N. Natural Killer Cell Regulation of B Cell Responses in the Context of Viral Infection[J]. Viral Immunology, 2020,33(4):334-341.
[35] Katz P, Whalen G, Cupps T R, et al. Natural killer cells can enhance the proliferative responses of B lymphocytes[J]. Cellular Immunology, 1989,120(1):270-276.
[36] Galli G, Nuti S, Tavarini S, et al. CD1d-restricted Help To B Cells By Human Invariant Natural Killer T Lymphocytes[J]. The Journal of Experimental Medicine, 2003,197(8):1051-1057.